MAPT and Alzheimer disease: Although lots researchers found high levels of MS4A6A were associated with increased risk of AD, and in relation to AD-related neurofibrillary pathology and tau phosphorylation in vitro [25-28], whether the loci associate with the neuroimaging or metabolic biomarkers are still unclear.